Agilon Health (NYSE:AGL – Get Free Report) and Q Biomed (OTCMKTS:QBIO – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Agilon Health and Q Biomed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agilon Health | 2 | 8 | 5 | 0 | 2.20 |
| Q Biomed | 0 | 0 | 0 | 0 | 0.00 |
Agilon Health presently has a consensus price target of $58.73, indicating a potential downside of 49.77%. Given Q Biomed’s higher probable upside, analysts clearly believe Q Biomed is more favorable than Agilon Health.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Agilon Health | -6.09% | -146.03% | -24.55% |
| Q Biomed | N/A | N/A | N/A |
Valuation and Earnings
This table compares Agilon Health and Q Biomed”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agilon Health | $5.82 billion | 0.34 | -$391.35 million | ($21.56) | -5.42 |
| Q Biomed | N/A | N/A | N/A | ($0.02) | N/A |
Q Biomed has lower revenue, but higher earnings than Agilon Health. Agilon Health is trading at a lower price-to-earnings ratio than Q Biomed, indicating that it is currently the more affordable of the two stocks.
Summary
Q Biomed beats Agilon Health on 5 of the 8 factors compared between the two stocks.
About Agilon Health
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About Q Biomed
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
